Rhabdomyosarcoma
14 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
Rhabdomyosarcoma| Treatment and condition | Where it stands | Trials |
|---|
| Archive Sample Retrieval + Biospecimen Collection + pH Low Insertion Peptide-exatecan Conjugate CBX-12 + Radiologic Imaging Procedure for rhabdomyosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ATEZOLIZUMAB + Vincristine + Irinotecan + Temozolomide for rhabdomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cyclophosphamide + VINORELBINE for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Filgrastim, peg-filgrastim + Liposomal irinotecan + Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide + VINORELBINE + Temozolomide for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + Cyclophosphamide + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, alveolar | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Questionnaire Administration + Radiation Therapy + IRINOTECAN HYDROCHLORIDE + DACTINOMYCIN + TEMSIROLIMUS + Cyclophosphamide + VINORELBINE + Vincristine Sulfate for rhabdomyosarcoma, embryonal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Peptide vaccine IPX for rhabdomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Proton beam radiation or external beam radiation or brachytherapy + Surgical Resection + DACTINOMYCIN + Vincristine + Cyclophosphamide for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vinorelbine for rhabdomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|